Nilutamide
Androgen Receptor Antagonist
DB00665
Approved Indication
For use in combination with surgical castration for the treatment of metastatic prostate cancer involving distant lymph nodes, bone, or visceral organs (Stage D2).
1
Targets
0
Resistance Mutations
2
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Nilutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. This blockade of androgen receptors may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.
Details
DrugBank ID
DB00665 ↗
Approval Date
1996-09-19
Molecular Weight
317.2207 g/mol
Drug Class
Androgen Receptor Antagonist
ATC Codes
L02BB02
Synonyms
Nilutamida, Nilutamide, Nilutamidum
PubChem
CID: 4493 ↗
ChEMBL
CHEMBL1274 ↗
SMILES
CC1(C)NC(=O)N(C1=O)C1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F
ADMET Profile
Computing properties…
Drug References (DrugBank)